Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Harvard Business School
Johnson and Johnson
Colorcon
Express Scripts

Last Updated: August 11, 2022

BIDIL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Bidil patents expire, and when can generic versions of Bidil launch?

Bidil is a drug marketed by Azurity and is included in one NDA.

The generic ingredient in BIDIL is hydralazine hydrochloride; isosorbide dinitrate. There are twenty-one drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the hydralazine hydrochloride; isosorbide dinitrate profile page.

US Patents and Regulatory Information for BIDIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Azurity BIDIL hydralazine hydrochloride; isosorbide dinitrate TABLET;ORAL 020727-001 Jun 23, 2005 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for BIDIL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Azurity BIDIL hydralazine hydrochloride; isosorbide dinitrate TABLET;ORAL 020727-001 Jun 23, 2005 See Plans and Pricing See Plans and Pricing
Azurity BIDIL hydralazine hydrochloride; isosorbide dinitrate TABLET;ORAL 020727-001 Jun 23, 2005 See Plans and Pricing See Plans and Pricing
Azurity BIDIL hydralazine hydrochloride; isosorbide dinitrate TABLET;ORAL 020727-001 Jun 23, 2005 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for BIDIL

See the table below for patents covering BIDIL around the world.

Country Patent Number Title Estimated Expiration
Australia 7365900 See Plans and Pricing
Canada 2383974 See Plans and Pricing
World Intellectual Property Organization (WIPO) 0117528 See Plans and Pricing
Canada 1308659 METHODE DE REDUCTION DE LA MORTALITE ASSOCIEE A L'INSUFFISANCE CARDIAQUE CONGESTIVE FAISANT APPEL A L'HYDRALAZINE ET AU DINITRATE D'ISOSOBIDE (METHOD OF REDUCING MORTALITY ASSOCIATED WITH CONGESTIVE HEART FAILURE USING HYDRALAZINE AND ISOSORBIDE DINITRATE) See Plans and Pricing
European Patent Office 1212053 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Express Scripts
McKinsey
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.